Table 6.

Gynecologic neoplasia in women with FFA.

First Author, Year	Type of Study	Studied Population	Gynecologic Neoplasia and Antiestrogenic Therapies
Banka 2014 [49]	Retrospective study	N = 62 patients with FFA N1 = 1 male N2 = 61 females	N1 = 2 (3%) received Tamoxifen
Buendía-Castaño 2018 [54]	Case-control study	N1 = 104 female FFA patients N2 = 208 age-matched controls	N1 = 8 (7.7%) FFA patients with breast cancer N2 = 5 (2,4%) controls with breast cancer OR 3.20 [95% CI 1.07–9.54], p = 0.028) N3 = 7 (6.7%) FFA patients with use of tamoxifen N4 = 2 (0.1%) controls with use of tamoxifen OR 14.89 [95% CI 2.42–91.68], p = 0.004
Imhof 2018 [50]	Retrospective study	N = 148 female FFA patients	N1 = 6 (4.1%) had history of Tamoxifen use for breast cancer
Moreno-Arrones 2019 [14]	Case-control study	N1 = 578 women N2 = 289 women with FFA N3 = 289 female controls N4 = 77 men N5 = 19 men with FFA N6 = 58 male controls	N1 = 13 (4.5%) controls with breast cancer N2 = 10 (3.5%) cases with breast cancer p = 0.52 N3 = 2 (0.7%) controls who had ovarian cancer N4 = 0 cases who had ovarian cancer p = 0.15 N5 = 5 (1.7%) controls who took Tamoxifen N6 = 6 (2.1%) cases who took Tamoxifen p = 0.76 N7 = 0 controls who took Raloxifen N8 = 6 (2.1%) cases who took Raloxifen p = 0.03
Heppt 2018 [47]	Retrospective study	N = 72 FFA patients N1 = 70 (97.2%) women N2 = 2 (2.8%) men	N1 = 3 (4.2%) history of breast cancer